ADLINE
CHEM LAB LIMITED

05th November, 2026

To,
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai - 400 001

Scrip Code: 524604

Dear Sir/Madam,

Sub.: Outcome of the meeting of the Board of Directors pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the provisions of Regulation 30 read with Part A of Schedule III and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held today, i.e., Thursday, 05th November, 2026, has inter alia, considered, approved, and taken on record the following items of business:

1. **Standalone Unaudited Financial Results:** The Board considered and formally approved the Standalone Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, prepared in accordance with the applicable Indian Accounting Standards (Ind AS).

2. **Limited Review Report:** The Board considered and adopted the Limited Review Report submitted by the Statutory Auditors of the Company on the aforesaid Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026. We hereby declare and confirm that the Statutory Auditors of the Company have issued the said Limited Review Report with an unmodified opinion.

Please note that the meeting of the Board of Directors commenced at 05:10 P.M. and concluded at 05:40 P.M.

The approved Standalone Unaudited Financial Results along with the Limited Review Report are enclosed herewith for your reference and records.

Kindly take on your record the aforesaid information and acknowledge the same.

Thanking you,

Yours faithfully,

For, Adline Chem Lab Limited

Vrushank Balkrushna Patel

Adline Chem Lab Limited Ahmedabad Gujarat

Vrushank Balkrushna Patel
Managing Director
DIN: 05310613

JAIN KEDIA & SHARMA
CHARTERED ACCOUNTANTS

1001-1002, 10th Floor, Abhijeet-III, Nr. Mithakhali Six Roads, Law Garden, Ahmedabad 380 006.
Tel.: 079-26449920, 079-26449930, 079-40032023 | **Email:** clients@jainkediasharma.com

The Board of Directors
ADLINE CHEMLAB LIMITED

Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended September 30, 2026 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2400 (Revised), "Engagements to Review Historical Financial Statements", issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain limited assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Kedia & Sharma
Chartered Accountants
FRN: 103920W

JAIN KEDIA & SHARMA
FRN 103920W
AHMEDABAD
CHARTERED ACCOUNTANTS

Tarak Shah
Partner
Membership No. 182100
UDIN: 26182100ICEVVY1448

Place: Ahmedabad
Date: 05/11/2026

ADLINE CHEM LAB LIMITED
A-514, Stellar, Opp. Arista Building, Sindhu Bhavan Road, Bodakdev, Ahmedabad - 380054, Gujarat, India
CIN : L35106GJ1988PLC010956
Ph.no.: 99799 41234 Email Id: secretarial.adlinechemlab@gmail.com Website : www.adlinechemlab.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September, 2026

(Rs in Lakhs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30th Sep 2026	30th June 2026	30th Sep 2025	30th Sep 2026	30th Sep 2025	31st Mar 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	-	-	-	-	-	-
Other Income	-	11.99	-	11.99	-	1.15
Total Income	-	11.99	-	11.99	-	1.15
Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of Stock in Trade	-	-	-	-	-	-
Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	-	-	-	-	-	-
Employee benefits expense	0.75	0.75	0.18	1.50	0.99	2.00
Finance costs	4.66	4.84	2.87	9.49	5.65	17.67
Depreciation and amortization expense	-	-	-	-	-	-
Other expenses	2.46	3.21	4.97	5.67	7.26	13.18
Total expenses	7.87	8.80	8.02	16.67	13.89	32.85
Profit/(loss) before exceptional items and tax	(7.87)	3.20	(8.02)	(4.67)	(13.89)	(31.70)
Exceptional Items	-	-	-	-	-	-
Profit/(loss) before tax	(7.87)	3.20	(8.02)	(4.67)	(13.89)	(31.70)
Tax expense:	0.88	0.81	(0.76)	0.07	(1.50)	3.59
Current tax	-	-	-	-	-	-
Prior period tax	-	0.81	-	-	-	3.59
Deferred tax	0.88	-	(0.76)	0.07	(1.50)	-
Profit (Loss) for the period from continuing operations	(8.75)	4.01	(7.26)	(4.75)	(12.39)	(28.11)
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
Profit/(loss) for the period	(8.75)	4.01	(7.26)	(4.75)	(12.39)	(28.11)
Other Comprehensive Income	-	-	0.15	-	0.30	-
Items that will not be reclassified to profit or loss (Net off tax)	-	-	0.15	-	0.30	-
Benefit due to actuarial valuation of gratuity	-	-	0.20	-	0.40	-
Deferred tax	-	-	(0.05)	-	(0.10)	-
Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
Total Comprehensive Income for the period	(8.75)	4.01	(7.11)	(4.75)	(12.09)	(28.11)
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00	585.00	585.00
Earnings per equity share (for continuing operation):						
Basic	(0.15)	0.07	(0.12)	(0.08)	(0.21)	(0.48)
Diluted	(0.15)	0.07	(0.12)	(0.08)	(0.21)	(0.48)
Earnings per equity share (for discontinued operation):						
Basic	(0.15)	0.07	(0.12)	(0.08)	(0.21)	(0.48)
Diluted	(0.15)	0.07	(0.12)	(0.08)	(0.21)	(0.48)
Earnings per equity share (for continuing & discontinued operation):						
Basic	(0.15)	0.07	(0.12)	(0.08)	(0.21)	(0.48)
Diluted	(0.15)	0.07	(0.12)	(0.08)	(0.21)	(0.48)

Notes :

1. This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended September 30, 2026.
2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on November 05, 2026, and approved by the Board of Directors at its meeting held on November 05, 2026. The Statutory Auditors Report does not have any qualification / modification.
3. Since Ind AS 108, 'Operating Segment' is not applicable to the company, the company has not disclosed any segment information.
4. EPS is not annualized for the quarter ended September 30, 2026, June 30, 2026 and September 30, 2025 and for the half year ended September 30, 2026 and September 30, 2025.
5. Other expenses includes Rs. 1.06 Lakhs penalty by BSE for non-appointment of a Company Secretary (CS) for the Quarter ended June-2026.
6. Other income amounting to Rs. 11.99 lakh reported for the quarter ended 30 June 2026 is attributable to the modification of borrowings pursuant to Ind AS adjustments.

Place: Ahmedabad
Date: 05/11/2026

For, ADLINE CHEMLAB LIMITED

MR. VRUSHANK BALKRUSHNA PATEL
MANAGING DIRECTOR
DIN:05310613

Adline Chem Lab Ahmedabad Gujarat

STANDALONE AUDITED STATEMENT OF ASSETS & LIABILITIES AS AT
September 30th ,2026

(Rs in Lakhs)

Particulars	As at 30th September 2026	As at 31st March 2026
ASSETS		
Current assets		
(a) Financial Assets		
(i) Cash and cash equivalents	7.47	6.55
(b) Other current assets	3.84	0.37
TOTAL ASSETS	**11.31**	**6.91**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	585.00	585.00
(b) Other Equity	(767.19)	(762.44)
Non-current liabilities	-	-
(a) Financial Liabilities	-	-
(i) Borrowings	189.49	180.27
(b) Provisions	-	-
(c) Deferred tax liabilities (Net)	2.41	2.34
Current liabilities	-	-
(a) Financial Liabilities	-	-
(i) Borrowings	-	-
(ia) Lease Liability	-	-
(ii) Trade payables	-	-
(iii) Other financial liabilities [other than those specified in item (c)]	0.47	1.01
(b) Other current liabilities	1.14	0.73
TOTAL EQUITY AND LIABILITIES	**11.31**	**6.91**

Place: Ahmedabad
Date: 05/11/2026

For, ADLINE CHEMLAB LIMITED

Adline Chem Lab Limited Ahmedabad Gujarat

MR. VRUSHANK BALKRUSHNA PATEL
MANAGING DIRECTOR
DIN:05310613

ADLINE CHEMLAB LIMITED

Standalone statement of Cash flow for the Half Year ended September 30th,2026

(Rs in Lakhs)

	Particulars		For the Half Year ended September 30,2026	For the Half Year ended March 31,2026
A	**Cash flow from Operating Activities**			
	Net Profit Before Tax		**(4.67)**	**(31.70)**
	Adjustments for:			
	Add	Interest Expense	5.65	11.33
	Add	Intrest Income	-	-
	Add	Provision for Gratuity	-	0.53
	Add	Changes due to Modification in Financial Liabilities	-	3.55
	Less	Gratuity written back	-	(1.15)
	Operating Profit / (Loss) before Working Capital Changes		**0.97**	**(17.44)**
	Adjustments for:			
	Increase/(Decrease) in Other Current Liabilities		(0.14)	0.73
	Increase/(Decrease) in Provisions		-	0.00
	(Increase)/Decrease in inventories		-	-
	(Increase)/Decrease in other current assets		(3.48)	0.86
	Cashflow generated from Operating Activities		**(2.64)**	**(15.83)**
	Income Tax Paid / Income Tax Refund (Net)		-	-
	Net Cashflow generated from Operating Activities A		**(2.64)**	**(15.83)**
B	**Cash flow from Investment Activities**			
	Purchase of Property , Plant and Equipment		-	-
	Sale of Property , Plant and Equipment		-	-
	Sale of Investments		-	-
	Purchase of Investments		-	-
	Share Application Money Received Back		-	-
	Dividend Income		-	-
	Intrest Income		-	-
	(Increase)/Decrease in short term loans & advances		-	-
	Net Cashflow generated from Investments Activities B		**-**	**-**
C	**Cash flow from Financiang Activities**			
	Share Listing & Processing Fees			
	Interest Expenses		(5.65)	(11.33)
	Proceedings from long term borrowing		-	-
	Repayment of long term borrowing		-	-
	Proceedings from Short term borrowing		-	-
	Repayment of Short term borrwing		-	-
	(Increase)/Decrease in other non-current assets		-	-
	(Increase) /Decrease in Short term Loans & Advances (Assets)		-	-
	Increase /(Decrease) in Borrowings (Liabilities)		9.21	27.94
	Increase/(Decrease) in Borrowing		-	-
	Increase/(Decrease) in other financial liabilities		-	(0.55)
	Net Cashflow generated from Financing Activities C		**3.56**	**16.06**
	Net Change in Cash & Cash Equivalents (A+B+C)		**0.92**	**0.22**
	Opening Cash & Cash Equivalents		6.55	6.32
	Closing Cash & Cash Equivalents		**7.47**	**6.55**

Place: Ahmedabad

Date: 05/11/2026

For, ADLINE CHEMLAB LIMITED

MR. VRUSHANK BALKRUSHNA PATEL

MANAGING DIRECTOR

DIN:05310613

Adline Chem Lab Limited Ahmedabad Gujarat